Phase II Trials in T-Cell Lymphoma: Romidepsin and Pegylated Liposomal Doxorubicin/Bexarotene
CME INFORMATION

OVERVIEW OF ACTIVITY
The annual American Society of Hematology (ASH) meeting is unmatched in its importance with regard to advancements in hematologic cancer and related disorders. It is targeted by many members of the clinical research community as the optimal forum in which to unveil new clinical data. This creates an environment each year in which published results and new information lead to the emergence of many new therapeutic agents and changes in the indications for existing treatments across virtually all malignant and benign hematologic disorders. As online access to posters and plenary presentations is not currently available, a need exists for additional resources to distill the information presented at the ASH annual meeting for those clinicians unable to attend but desiring to remain up to date on the new data released there. To bridge the gap between research and patient care, this CME activity will deliver a serial review of the most important emerging data sets from the latest ASH meeting, including expert perspectives on how these new evidence-based concepts can be applied to routine clinical care. This activity will assist medical oncologists, hematologists and hematology-oncology fellows in the formulation of optimal clinical management strategies and the timely application of new research findings to best-practice patient care.

LEARNING OBJECTIVES
• Consider the inclusion of single-agent romidepsin in the treatment algorithm for relapsed or refractory peripheral T-cell lymphoma.
• Integrate new and existing therapeutic strategies into the best-practice management of diffuse large B-cell lymphoma.
• Apply the results of emerging clinical research to the selection of optimal systemic therapy for patients with relapsed/refractory mantle-cell lymphoma.

ACCREDITATION STATEMENT
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT
Research To Practice designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

HOW TO USE THIS CME ACTIVITY
This CME activity contains slides and edited commentary. To receive credit, the participant should review the slide presentations, read the commentary, complete the Post-test with a score of 75% or better and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/5MJCASH2012/6/CME.

CONTENT VALIDATION AND DISCLOSURES
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process:

Steven M Horwitz, MD
Assistant Attending
Lymphoma Service
Division of Hematologic Oncology
Memorial Sloan-Kettering Cancer Center
New York, New York

Brad S Kahl, MD
Associate Professor
Director, Lymphoma Service
University of Wisconsin School of Medicine and Public Health
Associate Director for Clinical Research
UW Carbone Cancer Center
Madison, Wisconsin

Craig Moskowitz, MD
Clinical Director, Division of Hematologic Oncology
Attending Physician, Lymphoma and Adult BMT Services
Member, Memorial Sloan-Kettering Cancer Center
Professor of Medicine, Weill Medical College of Cornell University
New York, New York

Owen A O'Connor, MD, PhD
Professor of Medicine and Developmental Therapeutics
Director, Center for Lymphoid Malignancies
Columbia University Medical Center
College of Physicians and Surgeons
NewYork-Presbyterian Hospital
New York, New York


EDITOR — Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: Abbott Laboratories, Allos Therapeutics, Amgen Inc, ArQule Inc, Astellas, Bayer Healthcare Pharmaceuticals/Onyx Pharmaceuticals Inc, Biodexis Inc, BioGen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Cephalon Inc, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, EMD Serono Inc, Genentech BioOncology, Genomic Health Inc, ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company, Incyte Corporation, Lilly USA LLC, Medivation Inc, Millennium: The Takeda Oncology Company, Mundipharma International Limited, Novartis Pharmaceuticals Corporation, Regeneron Pharmaceuticals, Sanofi, Seattle Genetics, Spectrum Pharmaceuticals Inc and Teva.

RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS
— The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

This activity is supported by educational grants from Allos Therapeutics, Celgene Corporation, Genentech BioOncology/ Biogen Idec, Incyte Corporation, Millennium: The Takeda Oncology Company, Onyx Pharmaceuticals Inc, Sanofi and Seattle Genetics.

Last review date: March 2012
Expiration date: March 2013
This past Friday 8 clinical investigators ventured to Miami for our annual post-ASH lymphoma Think Tank. Over the course of more than 6 fascinating hours together we focused on a multitude of topics and as always recorded the proceedings, which will be available as an enduring activity in the coming months. While our engineers are busy de-umming (our little secret) and editing the audio, we thought we would hold you over with a taste of some of the new ASH NHL papers that were fodder for discussion and debate during Friday’s lymphoma extravaganza.

1. **Lenalidomide/rituximab**

The so-called R-squared regimen of the immunomodulatory agent lenalidomide (len) and rituximab (R) has generated considerable excitement among investigators, and at ASH we saw the results from a Phase II trial evaluating this combination alone or with dexamethasone for patients with relapsed indolent NHL or mantle-cell lymphoma (MCL) considered to be resistant to R. Of the 48 patients treated on the trial more than a third had a response, and the median progression-free survival was 18 months. These findings have raised hopes that len might help overcome R resistance and that in select populations such as the elderly this combination might become an alternative to aggressive treatment of relapsed disease — for example, with autologous stem cell transplant (ASCT).

2. **Two papers on MCL**

Another ASH NHL highlight was the presentation of a Phase II study of PCI-32765, an oral irreversible Bruton’s tyrosine kinase inhibitor, as a single agent in relapsed/refractory MCL. The results are compelling, as two thirds of the 39 patients in the study had objective responses and 35 remain on treatment. Importantly, none stopped therapy due to toxicity. Many investigators now have patients in their practices on trials who have experienced obvious prolonged benefit with this agent, and as a result significant excitement surrounds it and other small molecules, like the PI3 kinase inhibitor CAL-101 that is also under active investigation in a variety of NHL subtypes.

The rarity of MCL has made the definition of treatment benefits a challenge, and another important study reported at ASH attempted to better establish the effects of R in this disease. This effort from the UK evaluated the combination of fludarabine and cyclophosphamide with or without R, and while a high rate of infection was observed in these patients receiving fludarabine, substantial improvements in response rate and an almost doubling of progression-free survival reinforced the value of adding the CD20 antibody, which is now used routinely up front and often as maintenance treatment.
3. Two studies of diffuse large B-cell lymphoma (DLBCL)

Previous research with dose-adjusted EPOCH with R has shown promising results in untreated DLBCL, and this Phase IV trial of 81 patients with poor-prognosis disease (age-adjusted IPI of 1 or higher) reported an encouraging 62% 5-year progression-free survival rate. An ongoing Phase III Intergroup trial is comparing EPOCH-R to R-CHOP.

One of the biggest disappointments at ASH came from the much-awaited Phase III SWOG study comparing conditioning R/BEAM (carmustine, etoposide, cytarabine, melphalan) to $^{131}$I-tositumomab/BEAM for patients with DLBCL about to undergo ASCT. The trial results were flat-out negative, confounding the positive findings observed in the Phase II setting and forcing investigators back to the drawing board to look at higher doses of radioimmunotherapy as pretransplant conditioning.

4. Two papers on T-cell lymphoma

At ASH Dr Bertrand Coiffier presented an update of the Phase II pivotal study evaluating the selective inhibitor of histone deacetylase romidepsin in relapsed or refractory peripheral T-cell lymphoma (PTCL). This trial, which led to the FDA approval in this setting, evaluated 130 patients across PTCL subgroups, and these findings reveal higher response rates among individuals with the most common forms of the disease. This suggests that romidepsin may perhaps have more activity in common PTCL subtypes than initial data suggested.

In cutaneous T-cell lymphoma we saw the results of a Phase II trial investigating the interesting sequence of pegylated liposomal doxorubicin (PLD) — which has been shown to have high response rates and is known to concentrate in the skin — followed by the synthetic retinoid bexarotene (Bex). Perhaps because the study selected for patients with more aggressive disease, a 41% response rate (lower than reported in other trials) was observed with PLD and Bex did not increase the rate or duration of response. With the current shortage of PLD, not many patients are being treated with this agent.

Next up on this ASH series we go back to multiple myeloma and new reports on effective long-term disease control in older patients on continuing therapy.

Neil Love, MD
Research To Practice
Miami, Florida
Phase II Trials in T-Cell Lymphoma: Romidepsin and Pegylated Liposomal Doxorubicin/Bexarotene

Presentations discussed in this issue

Coiffier B et al. Analysis of patients with common peripheral T-cell lymphoma subtypes from a Phase 2 study of romidepsin in relapsed or refractory peripheral T-cell lymphoma. Proc ASH 2011;Abstract 591.


Straus DJ et al. Final results of Phase II trial of pegylated liposomal doxorubicin (PLD) followed by bexarotene (Bex) in advanced cutaneous T-cell lymphoma (CTCL). Proc ASH 2011;Abstract 882.

Slides from presentations at ASH 2011 and transcribed comments from a recent interview with Owen A O’Connor, MD, PhD (2/3/12) and from Steven M Horwitz, MD at a recent closed roundtable recording (3/9/12)
Results from a Pivotal, Open-Label, Phase II Study of Romidepsin in Relapsed or Refractory Peripheral T-Cell Lymphoma after Prior Systemic Therapy

Coiffier B et al.

*Proc ASH* 2011;Abstract 591.

Background

- Peripheral T-cell lymphomas (PTCLs) are a heterogeneous group of rare disorders resulting from clonal proliferation of mature post-thymic lymphocytes (*Ann Oncol* 1998;9:849).
- Currently, no agents are approved for use as first-line treatment of PTCL.
- Romidepsin is a structurally unique, selective inhibitor of histone deactylase (HDAC) approved for the treatment of patients with cutaneous T-cell lymphoma following ≥1 prior systemic therapies.

**Objective:**
- Confirm the efficacy of romidepsin in patients with relapsed or refractory PTCL.
Trial Design

Eligibility (n = 130)
- Histologically confirmed PTCL by central review for PTCL subtypes
- Relapsed disease or refractory to ≥1 systemic therapies
- No use of any investigational therapy within 4-6 weeks of study entry

* Patients with stable disease (SD), partial response (PR) or complete response/unconfirmed complete response (CR/CRu) could elect to extend therapy until progressive disease or another withdrawal criterion was met.

Primary endpoint:
- Rate of CR/CRu as determined by an independent review committee (IRC)


Response Rates: Overall IRC and Investigators’ Assessments (INA)

<table>
<thead>
<tr>
<th>Best response rate</th>
<th>IRC (n = 130)</th>
<th>INA (n = 130)</th>
</tr>
</thead>
<tbody>
<tr>
<td>ORR (CR/CRu + PR)*</td>
<td>25%</td>
<td>29%</td>
</tr>
<tr>
<td>CR/CRu†</td>
<td>15%</td>
<td>16%</td>
</tr>
<tr>
<td>CR</td>
<td>10%</td>
<td>15%</td>
</tr>
<tr>
<td>CRu</td>
<td>5%</td>
<td>2%</td>
</tr>
<tr>
<td>PR</td>
<td>11%</td>
<td>13%</td>
</tr>
<tr>
<td>SD</td>
<td>25%</td>
<td>17%</td>
</tr>
<tr>
<td>PD or N/E</td>
<td>49%</td>
<td>54%</td>
</tr>
</tbody>
</table>

ORR, objective response rate; PD, progressive disease; N/E, not evaluable

* Median time to response was 1.8 mo; duration of response was 16.6 mo by IRC.
† Median time to response was 3.7 mo; duration of response was 16.6 mo by IRC.

- Baseline disease characteristics, prior therapeutic regimen or number of prior therapies had no impact on the ability of patients to respond to romidepsin.

### Response Rates by Overall IRC Assessments in Patient Subgroups

<table>
<thead>
<tr>
<th>Subgroup (n = 130)</th>
<th>CR/CRu rate</th>
<th>ORR</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>%</td>
<td>%</td>
</tr>
<tr>
<td>PTCL subtype</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PTCL NOS (n = 69)</td>
<td>14</td>
<td>29</td>
</tr>
<tr>
<td>AITL (n = 27)</td>
<td>19</td>
<td>30</td>
</tr>
<tr>
<td>ALK-1-neg ALCL (n = 21)</td>
<td>19</td>
<td>24</td>
</tr>
<tr>
<td>Others (n = 13)</td>
<td>0</td>
<td>0</td>
</tr>
</tbody>
</table>

PTCL NOS, PTCL not otherwise specified; AITL, angioimmunoblastic T-cell lymphoma; ALK-1-neg-ALCL, ALK-1-negative anaplastic large-cell lymphoma

*Based on PTCL NOS, AITL and ALK-1-negative ALCL (n = 117)

- No meaningful differences were seen in ORR or CR/CRu rates based on sex, age, baseline disease characteristics, prior therapeutic regimen or number of prior therapies.


### Progression-Free Survival (PFS)

<table>
<thead>
<tr>
<th>Median PFS</th>
<th>IRC</th>
</tr>
</thead>
<tbody>
<tr>
<td>Overall (n = 130)</td>
<td>4 months</td>
</tr>
<tr>
<td>Achieved CR/CRu (n = 19)</td>
<td>18 months</td>
</tr>
<tr>
<td>With PR (n = 14)</td>
<td>7 months</td>
</tr>
<tr>
<td>With SD (n = 33)</td>
<td>6 months</td>
</tr>
<tr>
<td>With PD or N/E (n = 64)</td>
<td>&lt;2 months</td>
</tr>
</tbody>
</table>

- Patients who had achieved CR/CRu had substantially longer PFS than those in all other response categories.

Selected Drug-Related Adverse Events (AEs)

<table>
<thead>
<tr>
<th>Event (n = 131)*</th>
<th>All grades</th>
<th>Grade ≥3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nausea</td>
<td>54%</td>
<td>2%</td>
</tr>
<tr>
<td>Infections SOC†</td>
<td>18%</td>
<td>6%</td>
</tr>
<tr>
<td>Asthenia/fatigue</td>
<td>52%</td>
<td>5%</td>
</tr>
<tr>
<td>Thrombocytopenia</td>
<td>40%</td>
<td>23%</td>
</tr>
<tr>
<td>Vomiting</td>
<td>34%</td>
<td>4%</td>
</tr>
<tr>
<td>Diarrhea</td>
<td>23%</td>
<td>2%</td>
</tr>
<tr>
<td>Pyrexia</td>
<td>17%</td>
<td>4%</td>
</tr>
<tr>
<td>Neutropenia</td>
<td>29%</td>
<td>18%</td>
</tr>
<tr>
<td>Anemia</td>
<td>21%</td>
<td>5%</td>
</tr>
</tbody>
</table>

* Inclusive of 1 patient with a diagnosis of diffuse large B-cell lymphoma
† System organ class according to the Medical Dictionary for Regulatory Activities


Author Conclusions

- Romidepsin, as a single-agent, induced complete and durable responses in patients with relapsed or refractory PTCL.
- Romidepsin improved outcomes across all major PTCL subgroups, regardless of the number or type of prior therapies.
- These data demonstrated that romidepsin produced manageable toxicity in patients with relapsed or refractory PTCL.
- Based on the results from this Phase II study, romidepsin was approved by the US Food and Drug Administration for the treatment of patients with relapsed or refractory PTCL.

Investigator Commentary: Results from a Pivotal, Open-Label, Phase II Study of Romidepsin in Relapsed or Refractory PTCL

Romidepsin is one of 3 drugs that were approved for the treatment of T-cell lymphoma in the past 1 or 2 years. The original presentation of the investigators that led to the approval of romidepsin was based on 130 patients with relapsed or refractory PTCL. By IRC assessments, the ORR was 25% and 10% of the patients had CR.

However, the response rates presented in the abstracts at the recent ASH meeting were a lot higher than what was observed in the original presentation. This is because the meeting abstract presents a subset ORR analysis of the larger registration-directed study in the 3 most common PTCL subtypes (n = 117): PTCL NOS (29%), AITL (30%) and ALK-1-negative ALCL (24%). In the total patient population analysis (n = 130), the ORR is slightly lower. Overall, the data suggest that romidepsin may have more activity in the more common PTCL subtypes than what one may be led to believe by the larger data set of 130 patients.

Interview with Owen A O’Connor, MD, PhD, February 3, 2012

Final Results of Phase II Trial of Pegylated Liposomal Doxorubicin (PLD) Followed by Bexarotene (Bex) in Advanced Cutaneous T-Cell Lymphoma (CTCL)

Straus DJ et al.
Proc ASH 2011;Abstract 882.
Background

- Pegylated liposomal doxorubicin (PLD) is approved for the treatment of Kaposi’s sarcoma and concentrates highly in the skin.
- Previous studies have demonstrated the effectiveness of PLD in patients with advanced cutaneous T-cell lymphoma (CTCL) but without a strictly defined response criteria (Arch Dermatol 2008;144:727; Cancer 2003;98:993).
- Bexarotene (Bex) is a synthetic retinoid that has been reported to have an objective response rate (ORR) of about 50% in patients with relapsed or refractory CTCL (JCO 2001;19:2456; Arch Dermatol 2001;137:581).
- **Objective:**
  - Determine the true ORR for PLD and assess if the ORR and remission durations can be improved by sequential Bex following PLD in advanced or refractory CTCL.

Straus DJ et al. Proc ASH 2011;Abstract 882.

Trial Design

**Eligibility (n = 37)**

Advanced-stage or refractory CTCL

**Primary measure of skin response:**
- The Severity-Weighted Assessment Tool (SWAT)

**Secondary measures of skin response:**
- The composite assessment of index lesion severity
- Self-reported pruritus scale

Response assessments were performed after 8 weeks (PLD) and 16 weeks (Bex).

Straus DJ et al. Proc ASH 2011;Abstract 882.
### Efficacy Results (Abstract Only)

<table>
<thead>
<tr>
<th>Clinical parameter</th>
<th>n = 34</th>
</tr>
</thead>
<tbody>
<tr>
<td>ORR*</td>
<td>41%</td>
</tr>
<tr>
<td>Clinical complete response (CCR)</td>
<td>6%</td>
</tr>
<tr>
<td>Partial response (PR)</td>
<td>35%</td>
</tr>
<tr>
<td>Median PFS</td>
<td>4.82 months</td>
</tr>
</tbody>
</table>

CCR: Complete disappearance of skin lesions on examination

* Maximum responses were all seen after 16 weeks of PLD.


### Adverse Events (AEs) and Deaths (Abstract Only)

<table>
<thead>
<tr>
<th>Event, n</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Grade 3/4 serious AEs</td>
<td>9</td>
</tr>
<tr>
<td>Tumor pain</td>
<td>4</td>
</tr>
<tr>
<td>Grade 3 hand-foot syndrome</td>
<td>2</td>
</tr>
<tr>
<td>Infection — unknown ANC-skin (cellulitis)</td>
<td>1</td>
</tr>
<tr>
<td>Infection — normal ANC-skin (cellulitis)</td>
<td>1</td>
</tr>
<tr>
<td>Neutropenia</td>
<td>1</td>
</tr>
<tr>
<td>Deaths</td>
<td></td>
</tr>
<tr>
<td>Progressive disease</td>
<td>18</td>
</tr>
<tr>
<td>Congestive heart failure*</td>
<td>1</td>
</tr>
</tbody>
</table>

* Patient (n = 1) was pretreated for LVEF of 60%

Author Conclusions

- With strict criteria, ORR for PLD is one of the highest reported for single agents in CTCL.
- However, the ORR for PLD determined in this study is lower than previously reported.
- The study population contained a high proportion of patients with advanced disease (data not shown) as reflected in the poor survival outcomes.
- Sequentially administering Bex did not increase the response rate or duration (data not shown).


Investigator Commentary: Final Results of a Phase II Trial of PLD followed by Bex in Advanced CTCL

This study, of which I was a part, was designed to determine whether clinical responses can be induced with a relatively safe chemotherapy and then maintained with a milder agent like Bex. The results showed a reasonable response rate of about 40% with liposomal doxorubicin, although others in the literature report a rate of about 80%.

This study did not demonstrate a benefit in terms of durability of response with Bex, although we have seen a couple of patients who have had long-term remissions after follow-up with maintenance therapy. I believe the study was rationally designed but it inadvertently selected for a highly aggressive, somewhat atypical patient population. This is because a patient with mycosis fungoides suitable for chemotherapy but never having received Bex is unusual. Such a patient tends to start off with an early aggressive disease. This may explain why the durability of responses to Bex was so short.

Overall, these data demonstrate that PLD is an active drug but it is uncertain whether maintenance therapy with Bex improves response.

*Interview with Steven M Horwitz, MD, March 9, 2012*